Latest News

If you are wondering whether goeasy at around $33.80 is starting to look mispriced, this breakdown will help you see how the current share price stacks up against several valuation yardsticks. The stock has seen steep declines, with returns of 70.7% over 7 days, 72.2% over 30 days, 74.3% year to date and 76.6% over the past year, which has sharply changed how the market is pricing its risks and potential. Recent coverage has focused on the share price slump itself and what it might say about...

Genting Singapore launches shareholder approved buyback Genting Singapore (SGX:G13) has started repurchasing its own shares under a shareholder approved buyback mandate. The mandate authorizes the company to buy back up to 10% of its issued share capital. See our latest analysis for Genting Singapore. At a share price of SGD0.675, Genting Singapore has a 30 day share price return of 12.34% decline and a 1 year total shareholder return of 4.35% decline. This suggests recent momentum has been...

In early March 2026, Bilfinger SE reported fourth-quarter 2025 results showing sales of €1,422.6 million and net income of €42.2 million, while proposing a higher dividend of €2.80 per share for 2025, up from the €2.40 per share paid the previous year. The decision to raise the dividend despite lower quarterly net income and earnings per share suggests management is prioritizing shareholder returns and signaling confidence in the company’s cash generation beyond the latest earnings...

Earlier this month, BANF announced a collaboration with Silicon Labs to integrate the ultra‑low‑power BG22 Bluetooth LE SoC and Secure Vault security into BANF’s new in‑tire, battery‑free sensor platform for autonomous and connected vehicles. By digitizing real‑time tire conditions with on‑tire data processing and wireless power transfer, the partnership turns tires into high‑value data sources for safety, fleet management, and future predictive services. We’ll now examine how embedding...

Silvaco Group (SVCO) surprised the market with quarterly results that came in ahead of expectations, along with revenue guidance above earlier forecasts and cost cuts tracking better than management initially outlined. See our latest analysis for Silvaco Group. Silvaco Group’s recent earnings beat and upbeat guidance have been met with sharp share price momentum, with a 7 day share price return of 53.5% and a year to date share price return of 22%, even though the 1 year total shareholder...

Balyo (ENXTPA:BALYO) has reported its FY 2025 first half results with revenue of €13.3 million and a net loss of €7.9 million, equivalent to a basic EPS loss of €0.05, while the trailing twelve month figures show revenue of €31.4 million and a net loss of €12.9 million. Over recent periods the company has seen revenue move between €13.8 million and €15.3 million per half year, with basic EPS losses ranging from €0.06 to €0.22. This keeps the story firmly focused on how quickly margins can...

Safety Insurance Group (SAFT) is in focus after reporting an improved combined ratio of 99% in 2024, a well covered dividend, and a 4.2% yield on its investment portfolio. See our latest analysis for Safety Insurance Group. The share price sits at $73.53 after a 1 day share price return of 0.40% and a 7 day share price return of 1.21%. However, the 30 day share price return of 7.31% and year to date share price return of 2.88% point to fading short term momentum. The 3 year total shareholder...

Townsquare Media (TSQ) FY 2025 Earnings Snapshot Townsquare Media (TSQ) has wrapped up FY 2025 with Q4 revenue of US$106.5 million and a basic EPS loss of US$0.32, while trailing twelve month figures show revenue at US$427.4 million and a basic EPS loss of US$0.71. Over recent quarters the company has seen revenue move from US$117.8 million in Q4 2024 to US$106.5 million in Q4 2025, with EPS shifting from a profit of US$1.59 to a loss of US$0.32. This sets up a story where revenue is...

Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference. The updates covered exercise capacity outcomes, effectiveness across patients with and without hypertension, and safety during treatment interruption and restart. The new analyses expand the clinical profile of MYQORZO, a recently approved oHCM therapy, and add detail on how the drug performs in real treatment scenarios. Cytokinetics...

Wondering whether ServisFirst Bancshares is attractively priced at its current level? This article focuses squarely on what the recent share performance might be telling you about value. The stock last closed at US$73.73, with returns of 2.7% year to date, a 14.4% decline over the past month, and a 9.7% decline over the past year, while still showing a 35.2% gain over three years and 31.1% over five years. These mixed returns have kept ServisFirst Bancshares on the radar for investors who...

Wondering if United Bankshares at around US$39.38 is still a fair deal or starting to look stretched? This article breaks down what the current share price might be implying about value. The stock’s returns range from a 1.4% decline over the last 7 days and a 10.7% decline over the last 30 days, to gains of 2.6% year to date, 17.5% over 1 year, 25.7% over 3 years and 25.2% over 5 years. These figures can mean very different things depending on how you think about risk and timing. Recent...

Telos (TLS) just closed out FY 2025 with Q4 revenue of US$46.8 million and a basic EPS loss of US$0.22, capping a year in which trailing twelve month revenue came in at US$164.8 million and EPS on the same basis was a loss of US$0.50. Over recent quarters the company has seen revenue move from US$26.4 million in Q4 2024 to US$30.6 million in Q1 2025, US$36.0 million in Q2, US$51.4 million in Q3, and US$46.8 million in Q4, while quarterly basic EPS losses ranged between US$0.03 and US$0.22...

Lifecore Biomedical (LFCR) just posted its FY 2025 fourth quarter numbers, with revenue of US$36.4 million and a basic EPS loss of US$0.06. This sets the tone for a year where the trailing twelve months show revenue at about US$129.5 million and a basic EPS loss of US$0.92. Over recent quarters, revenue has moved from US$24.7 million in Q1 FY 2025 to US$31.1 million in Q3 and then US$36.4 million in Q4. Quarterly basic EPS losses ranged from US$0.53 in Q1 to US$0.29 in Q3 and US$0.06 in Q4,...

Zepp Health (ZEPP) has wrapped up FY 2025 with fourth quarter revenue of US$85.2 million and a basic EPS loss of US$0.69, setting the tone for how you might read the full year at the current share price of US$16.22. The company has seen quarterly revenue move from US$59.5 million in Q4 2024 to US$85.2 million in Q4 2025, while basic EPS over that stretch has shifted from a loss of US$2.29 to a loss of US$0.69. This puts the focus squarely on how sustainably margins can tighten those losses...

VinFast Auto (NasdaqGS:VFS) has just posted another loss making quarter, with Q3 FY 2025 revenue of about ₫18.1 trillion and basic EPS of a loss of ₫10,238.74, set against a trailing twelve month revenue base of roughly ₫67.5 trillion and a cumulative loss of about ₫92.5 trillion. Over recent periods the company has seen quarterly revenue move from about ₫8.7 trillion in Q2 FY 2024 to ₫12.3 trillion in Q3 FY 2024, ₫16.3 trillion in Q1 FY 2025 and now ₫18.1 trillion in Q3 FY 2025, while...

Latest FY 2025 Earnings Snapshot WaterBridge Infrastructure (WBI) just posted its FY 2025 numbers with third quarter revenue of US$123.25 million and a basic EPS loss of US$0.02, while net income excluding extra items was a loss of US$0.67 million. The company has seen revenue move from US$89.80 million in the third quarter of 2024 to US$123.25 million in the same period of 2025. The trailing twelve month revenue figure in the dataset stands at US$733.30 million with a net loss of US$91.25...

Why Telstra Group’s ongoing buy-back matters now Telstra Group (ASX:TLS) has updated the market on its ongoing on-market share buy-back, reporting a cumulative 138,864,731 shares repurchased, including 1,951,316 shares on the latest trading day. This continued capital return shapes Telstra Group’s share count, affects per share metrics, and gives you another factor to weigh alongside earnings, dividends and the current A$5.24 share price. See our latest analysis for Telstra Group. The...

Director Estienne de Klerk’s on market purchase of an additional 65,000 Growthpoint Properties Australia (ASX:GOZ) stapled securities, lifting his holding to 1,940,457, has put insider alignment and governance firmly in focus for investors. See our latest analysis for Growthpoint Properties Australia. At a share price of A$2.14, Growthpoint’s 1 month share price return of 3.6% and 3 month share price return of 12.65% sit against a 1 year total shareholder return of 0.73%. This suggests recent...

How Aalberts Stock Has Been Performing Recently Aalberts (ENXTAM:AALB) has moved lower in the very short term, with a 1 day decline of about 1% and a 7 day decline of about 1.4%, drawing fresh attention from investors. Over the past month the share price shows a decline of about 10%. Over the past 3 months it shows a gain of roughly 11%, offering a mixed picture for recent traders and for longer holding periods. See our latest analysis for Aalberts. With the share price at €31.42, Aalberts...

InnoCare Pharma recently dosed the first healthy volunteer in a China clinical trial of ICP-538, an oral VAV1-directed molecular glue degrader for autoimmune diseases, marking the first VAV1 degrader to reach trials in China and only the second globally. This move positions InnoCare at the forefront of a new class of targeted immunology drugs, in an area where no VAV1-focused therapies are yet approved worldwide. We’ll now examine how advancing ICP-538, a first-in-China VAV1 degrader, could...

In early March 2026, NTT DOCOMO, StarHub and ServiceNow announced a joint initiative to build an AI‑driven, autonomous roaming resolution model on the ServiceNow AI Platform, aiming to standardize and automate how carriers identify and fix international roaming issues for travelers. This collaboration is material because it seeks to cut manual support, improve reliability for roaming customers, and create a globally scalable, shared operational framework between mobile operators. Next, we’ll...

Gaztransport & Technigaz (GTT) recently received an order from HD Korea Shipbuilding & Offshore Engineering for the LNG tank design of a Sonangol-owned carrier, to be built at HD Hyundai Samho and equipped with GTT’s Mark III Flex membrane containment system for delivery in the second quarter of 2028. This contract highlights continued adoption of GTT’s containment technology by leading Korean yards and reinforces its role in upcoming LNG shipping projects. We’ll now examine how this new LNG...

Genscript Biotech has reported its full-year 2025 results, with sales rising to US$959.53 million while the company moved from a prior-year net income of US$2.96 billion to a net loss of US$532.83 million, alongside higher basic and diluted losses per share. A key driver of this sharp swing in reported profitability is the absence of the previous year’s very large one-time unrealised gain from deconsolidation, which means the latest figures chiefly reflect the underlying operating profile...

Apellis Pharmaceuticals recently added Mikael Dolsten, M.D., Ph.D., former chief scientific officer of Pfizer, to its board of directors, bringing decades of high-level research and development leadership across major global drug makers. This appointment, alongside growing analyst interest in Apellis’s key products Empaveli and Syfovre, underscores how external experts view the company’s pipeline and commercial portfolio as increasingly relevant in rare kidney disease and eye care...